RSC Advances
Paper
endothelial cells by curcumin, Cell Growth Differ., 1998, 9,
305–312.
6 J. van E. Marjan, E. Teuling, C. M. S. Yvonne, et al., Research
time- and dose-dependent effects of curcumin on gene
expression in human colon cancer cells, J. Carcinog., 2004,
3, 17.
and survival of tumor cells, Arzneim. Forsch., 2006, 56, 474–
482; (b) E. Kovacs, S. Link and U. Toffol-Schmidt,
Cytostatic and cytocidal effects of mistletoe (Viscum
album L.) quercus extract Iscador, Arzneim.-Forsch., 2006,
56, 467–473; (c) G. Seifert, P. Jesse, A. Laengler, et al.,
Molecular mechanisms of mistletoe plant extract-induced
apoptosis in acute lymphoblastic leukemia in vivo and in
vitro, Cancer Lett., 2008, 264, 218–228.
7 J. M. Holy, Curcumin disrupts mitotic spindle structure and
induces micronucleation in MCF-7 breast cancer cells,
Mutat. Res., Genet. Toxicol. Environ. Mutagen., 2002, 518, 16 W. B. Park, S. Y. Lyu, J. H. Kim, et al., Inhibition of tumor
71–84.
growth and metastasis by Korean mistletoe lectin is
associated with apoptosis and antiangiogenesis, Cancer
Biother.Radiopharm., 2001, 16, 439–447.
8 (a) F. Yang, G. P. Lim, A. N. Begum, et al., Curcumin Inhibits
Formation of Amyloid B Oligomers and Fibrils, Binds
¨
Plaques, and Reduces Amyloid In Vivo, J. Biol. Chem., 2005, 17 (a) M. Schink, W. Troger, A. Dabidian, et al., Mistletoe
280, 5892–5901; (b) R. W. McDonald, W. Bunjobpon,
T. Liu, et al., Synthesis and anticancer activity of
nordihydroguaiaretic acid (NDGA) and analogues, Anti-
Cancer Drug Des., 2001, 16, 261–270; (c) T. Choshi,
S. Horimoto, C. Y. Wang, et al., Synthesis of
Extract Reduces the Surgical Suppression of Natural Killer
Cell Activity in Cancer Patients. A Randomized Phase III
Trial, Forsch. Komplementarmed, 2007, 14, 9–17; (b)
L. Heinzerling, B. V. Von, C. Liebenthal, et al.,
Immunologic effector mechanisms of
a standardized
dibenzoylmethane
mutagenicity in Salmonella typhimurium, Chem. Pharm.
Bull., 1992, 40, 1047; (d) J. Ishida, M. Kozuka, H. K. Wang,
derivatives
and
inhibition
of
mistletoe extract on the function of human monocytes and
lymphocytes in vitro, ex vivo, and in vivo, J. Clin. Immunol.,
2006, 26, 347–359; (c) B. Liu, H. J. Bian and J. K. Bao, Plant
lectins: potential antineoplastic drugs from bench to
clinic, Cancer Lett., 2010, 287, 1–12.
et
al.,
Antitumor-promoting
effects
of
cyclic
diarylheptanoids on Epstein-Barr virus activation and two-
stage mouse skin carcinogenesis, Cancer Lett., 2000, 159, 18 U. Weissenstein, M. Kunz, K. Urech, et al., Interaction of
135–140.
standardized mistletoe (Viscum album) extracts with
chemotherapeutic drugs regarding cytostatic and cytotoxic
effects in vitro, BMC Complementary Altern. Med., 2014, 14, 6.
9 P. Anand, et al., Bioavailability of Curcumin: Problems and
Promises, Mol. Pharm., 2007, 4, 807–818.
10 R. Mishra, M. K. Das, S. Singh, et al., Articulatin-D induces 19 Y. L. Zhao, X. Y. Wang, L. X. Sun, et al., Cytotoxic
apoptosis via activation of caspase-8 in acute T-cell
leukemia cell line, Mol. Cell. Biochem., 2017, 426, 87–99.
constituents of Viscum coloratum, Z. Naturforsch. C, 2012,
67, 129–134.
11 R. Grossarth-Maticek and R. Ziegler, Randomised and non- 20 D. Lou, L. Zhang, W. Sun, et al., Determination of Curcumin
randomised prospective controlled cohort studies in
matched-pair design for the long-term therapy of breast
in Rat Plasma by HPLC and Study of its Pharmacokinetics,
Chin. J. Mod. Appl. Pharm., 2011, 28, 870–873.
cancer patients with a mistletoe preparation (Iscador): a re- 21 E. S. E. El-Awady, Y. M. Moustafa, D. M. Abo-Elmatty, et al.,
analysis, Eur. J. Med.Res., 2006, 11, 485–495.
Cisplatin-induced
cardiotoxicity:
mechanisms
and
12 P. J. Goebell, T. Otto, J. Suhr, et al., Evaluation of an
Unconventional Treatment Modality with Mistletoe Lectin
cardioprotective strategies, Eur. J. Pharmacol., 2011, 650,
335–341.
to Prevent Recurrence of Supercial Bladder Cancer: A 22 G. Chvetzoff, B. Bonnotte and B. Chauffert, Anticancer
´
Randomized Phase ii Trial, J. Urol., 2002, 168, 72–75.
chemotherapy. prevention of toxicity, La Presse Medicale,
13 G. B. Sela, M. Wollner, L. Hammer, et al., Mistletoe as
1999, 27, 2106–2112.
complementary treatment in patients with advanced non- 23 V. B. Pai and D. M. C. Nahata, Cardiotoxicity of
small-cell lung cancer treated with carboplatin-based Chemotherapeutic Agents, Drug Saf., 2000, 22, 263–302.
combinations: a randomised phase II study, Eur. J. Cancer, 24 L. I. wen Jun, Z. H. E. N. Yong-Xing and L. I. Yan-Fu,
2013, 49, 1058–1064.
Pharmacokinetics of carboplatin and cisplatin in rats,
14 C. Maletzki, M. Linnebacher, R. Savai, et al., Mistletoe lectin
Chin. J. Pharm., 1991, 22, 5.
has a shiga toxin-like structure and should be combined 25 N. K. Ibrahim, N. Desai, S. Legha, et al., Phase I and
with other Toll-like receptor ligands in cancer therapy,
Cancer Immunol. Immunother., 2013, 62, 283–1292.
pharmacokinetic study of ABI-007, a Cremophor-free,
protein-stabilized, nanoparticle formulation of paclitaxel,
15 (a) M. Harmsma, M. Ummelen, W. Dignef, et al., Effects of
mistletoe (Viscum album L.) extracts Iscador on cell cycle
Clin. Cancer Res., 2002, 8, 1038–1044.
27804 | RSC Adv., 2020, 10, 27794–27804
This journal is © The Royal Society of Chemistry 2020